The specificity of Hiltonol and its efficacy at low dose in targeting and activating tumor-suppressors, PKR and OAS, plus the dampening of the tumor microenvironment offer a promising potential for developing Hiltonol+++ into a powerful and selective anticancer cocktail drug for lung cancer treatment. This evidence concerns the gene EIF2AK2 and neoplasm.